Subscribe to the newsletterForward | Contact | www.lyonbiopole.com   October 2014
 
A LA UNE
11/28/2014 - Lyonbiopole Private Inv€stment Day's 6th edition

For the 6th time, Lyonbiopole organizes the Private Inv€stment Day on Friday, November 28th 2014, from 8.00 am to 3.00 pm. This event, dedicated to SMEs and private investors, aims to foster interactions between companies, new entrepreneurs and investors of various kind. This day will be organized around moments of networking (roundtables, testimony and breaks) and company and project presentations.
Contact: Kevin Romani, SMEs Developement Director - kevin.romani@lyonbiopole.com

Learn more


10/10/2014 - Partnering Day and BlueSky Meeting 2014

Stimulating innovation was the leitmotif of this new edition of Lyonbiopole Partnering Days held at the WTC Grenoble Friday, October 10th. A majority of the cluster's members from Lyon and Grenoble neraly 250 participants attended the event to incite the emergence of tomorrow's public/private R&D partenrship. The program is structured around three key moments: 14 brainstorming roundtables, the BlueSky Meeting with the presentation of 20 innovative technological products and ideas for collaborative projects and, finally, a three industrial groups discussion on open innovation and R&D collaborative strategies.
Contact: Claudia Chagneau, R&D Project Manager - claudia.chagneau@lyonbiopole.com

Learn more


10/7-8/2014 - Lyonbiopole announces its collaboration with MLSC

Lyonbiopole strengthens its presence in Boston and announces its collaboration with the Massachusetts Life Science Center. As part of the United States East Coast Mission led by Gérard Collomb, Mayor of Lyon and President of Greater Lyon organized by ONLYLYON, Lyonbiopole and the MLSC (Massachussets Life Sciences Center) announce collaboration for setting up collaborative projects under the "Universal partnership program".
Contact: Kevin Romani, SME's Devlopment Director - kevin.romani@lyonbiopole.com

Learn more



ZOOM SUR
Erytech Pharma

Erytech Pharma, a bio-pharmaceutical company and a Lyonbiopole member, is specialized in encapsulation. The company has just completed a fundraising of € 30 million on Euronext and announced at the same time the positive Phase III results from its pivotal study with GRASPA® in the treatment of acute Lyomphoblastic Leukemia. Rewarded on 21 October 2014 by EuropaBio 's Most Innovative European biotech SMEs trophy, Erytech now heads to the United States with a new patent pending in the area of asparaginase.

Learn more



A LA UNE
11/03/2014 - Meet major health actors in Japan on the occasion of Bio Europe (Frankfurt)

Lyonbiopole and its bioXclusters European partners (Biocat, bioPmed and BioM) organize on November 3rd, 2014 (from 15:00 to 18:00), during BIO Europe (Frankfurt) a meeting between Japanese and European players of the Health sector. This session provides a unique opportunity for European companies and clusters participating to the BIO-Europe fair to get an overview of the strengths of the health sector in Japan and to forge links with the Association of bio-industries in Japan (JBA), gathering the four major national clusters and their companies.
Contact: Emilie Roméo, European Project manager -emilie.romeo@lyonbiopole.com

Learn more


11/12-15/2014 - MEDICA-COPAMED Exhibition

Lyonbiopole and I-Care Cluster, in partnership with UbiFrance invite companies of the Rhône-Alpes region to participate to MEDICA COPAMED-2014 Exhibition wich will be held from  November 12th to 15th 2014 in Düsseldorf (Germany). Attend Europe's largest conference on MedicalesTechnologies & Medical Devices theme.
Contact: Simon Gudin, SMEs Development Project Manager - simon.gudin@lyonbiopole.com

Learn more


11/19/2014 - Open Innovation Day with Becton Dickinson

Are you targeting the MedTech market? This day will give you unique opportunity to get valuable information about the Market segments addressed by BD, the products, and the innovation targets of some of the business units from BD Medical and BD Diagnostics segments and to hear about their R&D fields of interest and technological road map overview. You should also present your unique and innovative capabilities and know-how (pitch session and/or speed meeting).
Contact: Simon Gudin, SMEs Devlopment Project Manager - simon.gudin@lyonbiopole.com

Learn more



AGENDA
Bio-Europe 2014
From November 3rd to 5th, 2014 - Frankfurt, Germany
Medica Copamed
From November 12th to 15th 2014 - Dusseldorf, Germany
EnterNext Tech Conference
November 17th, 2014 - Paris , France
4th Munich Biomarker Conference
From November 25th to 26th, 2014 - Munich, Germany
Private Inv€stment Day
November 28th, 2014 - Lyon, France
Biovision 2015
From April 15th to 16th, 2015, Lyon - France
2015 BIO International Convention
From June 15th to 16th, 2015, Philadephia - US
 
A LA UNE
10/2014 - Horizon 2020 Health - Calls for projects open

Several calls for projects in the H2020 "Health, demographic change and well-being" challenge, are open ("Calls H2020-PHC-2015 one-step" are still open: deadline 2/24/2015). They are designed to support collaborative projects to improve the quality of life of European citizens and the economic viability of health systems. Other calls related to health (like NMP program) or multidisciplinary programs like FET (Future Emerging Technologies) are open. More information here
Contact: Emilie Romeo, European Project Manager - emilie.romeo@lyonbiopole.com

10/2014 - IMI 2 call for projects open

The Innovative Medicines Initiative (IMI) launched its first call for projects under the IMI 2 on July 9. The topics proposed in the first call are: - Translational Approaches to disease modifying therapy of type 1 diabetes mellitus - Discovery and validation of novel endpoints dry age-related macular degeneration and diabetic retinopathy. Deadline for submission: November 12, 2014. IMI encourages the participation of SMEs, patient organizations, regulatory authorities, academic teams, industry, hospitals and other organizations. Lyonbiopole supports you to build up European projects
Contact: Emilie ROMEO, European Project Manager - emilie.romeo@lyonbiopole.com

Learn more


10/2014 - H2020 SME Instrument

H2020 program includes the SME instrument. It aims to fill gaps in the high-risk funding of innovation and give a strong boost to reach innovation. It targets the highly innovative SMEs with a strong ambition to develop, grow and internationalize;  focusing on the delivery of new products, services or processes on the market. For SMEs in the health sector, the SME instrument is focused on the PHC-12 Clinical research for the validation of biomarkers and / or diagnostic medical devices line. The project can be presented by a single SME, and different phases depending on the maturity of the project.  Reminder of deadlines in 2014: Phase 1 & 2 projects = 12/17/2014. Lyonbiopole supports you to build up European projects.
Contact: Emilie Romeo, European Project Manager - emilie.romeo@lyonbiopole.com

Learn more



A LA UNE
10/13-17/2014 - Trade mission during BIO Japan

With more than 6000 partnering meetings over 3 days, and a fair representation of Western and Eastern companies, BIO Japan is now one of the main partnering event in Asia. 4 members of Lyonbiopole participated to the trade mission organized by the French Trade Agency Ubifrance/DGE. It was the largest French delegation during BIO Japan. Beside their participation to BIO Japan, the participants also had the chance to visit the Takeda Corporate R&D center, in order to gain insight on the Japanese market, whici is still the 3rd market in the world, and to present their company at BIO Japan, during a seminar dedicated to France.
Contact: Simon Gudin, SMEs Development Project Manager - simon.gudin@lyonbiopole.com

Learn more


10/29/2014 - ImmunID to present at Cavendish Global Health Impact Forum

ImmunID, an immune molecular diagnostics company, announced it will be presenting at the Cavendish Global Health Impact Forum taking place November 10-13th at Oxford University in the United Kingdom. The Forum's aim is to help family offices and foundations to develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within the health sector and the life sciences.

Learn more


27/10/2014 - France’s National Research Agency selects the OPTIVAC project

Imaxio announced that it has been awarded of a 600K€ funding by the French National Research Agency for the OPTIVAC project: “leveraging On t-cell immune resPonse To Improve influenza VACcines”. The aim of the OPTIVAC project is to improve the efficacy of vaccines for seasonal influenza and current pandemics. To achieve this, it will develop a candidate vaccine made of a recombinant, proprietary, and highly  immunogenic version of the influenza virus nucleoprotein (NP).

Learn more


10/20/2014 - Calixar and Aston University together in collaborative research to tackle multidrug resistance targets

The annual CASE competition for collaborative training awards provides students with a first-rate research training experience, allowing top quality bioscience graduates to undertake research, leading to a PhD.

Learn more


10/14/2014 - Imaxio signs an option for a license agreement with the DKFZ

Imaxio announces that it has signed an option for a license agreement with the world-renowned German Center for Cancer Research (DKFZ – Deutsches Krebsforschungszentrum), based in Heidelberg. The financial terms of the agreement were not disclosed.

Learn more


10/06/2014 - CleveXel Pharma to license two new oncology patents 

CleveXel Pharma, a highly experienced pharmaceutical developer that conforms fully with global regulatory compliance, announces that it has been granted a license by the SATT Sud Est, a technology transfer accelerator in South Eastern France (Societe d’Acceleration du Transfert de Technologies Sud Est), to exploit two patents.

Learn more

 
© Lyonbiopole 2019  |  CREDITS  |  LEGAL NOTICE  |